119 related articles for article (PubMed ID: 8865318)
1. In vivo buccal delivery of the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs.
Hoogstraate AJ; Coos Verhoef J; Pijpers A; van Leengoed LA; Verheijden JH; Junginger HE; Boddé HE
Pharm Res; 1996 Aug; 13(8):1233-7. PubMed ID: 8865318
[TBL] [Abstract][Full Text] [Related]
2. In-vivo buccal delivery of fluorescein isothiocyanate-dextran 4400 with glycodeoxycholate as an absorption enhancer in pigs.
Hoogstraate AJ; Verhoef JC; Tuk B; Pijpers A; van Leengoed LA; Verheijden JH; Junginger HE; Boddé HE
J Pharm Sci; 1996 May; 85(5):457-60. PubMed ID: 8742934
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in buccal drug delivery and absorption--in vitro and in vivo studies.
Junginger HE; Hoogstraate JA; Verhoef JC
J Control Release; 1999 Nov; 62(1-2):149-59. PubMed ID: 10518646
[TBL] [Abstract][Full Text] [Related]
4. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo.
Luessen HL; de Leeuw BJ; Langemeÿer MW; de Boer AB; Verhoef JC; Junginger HE
Pharm Res; 1996 Nov; 13(11):1668-72. PubMed ID: 8956332
[TBL] [Abstract][Full Text] [Related]
5. Sodium glycodeoxycholate and sodium deoxycholate as epithelial permeation enhancers: in vitro and ex vivo intestinal and buccal bioassays.
Brayden DJ; Stuettgen V
Eur J Pharm Sci; 2021 Apr; 159():105737. PubMed ID: 33524502
[TBL] [Abstract][Full Text] [Related]
6. N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug buserelin in vitro (Caco-2 cells) and in vivo (rats).
Thanou M; Florea BI; Langemeÿer MW; Verhoef JC; Junginger HE
Pharm Res; 2000 Jan; 17(1):27-31. PubMed ID: 10714604
[TBL] [Abstract][Full Text] [Related]
7. Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis.
Kiesel L; Sandow J; Bertges K; Jerabek-Sandow G; Trabant H; Runnebaum B
J Clin Endocrinol Metab; 1989 Jun; 68(6):1167-73. PubMed ID: 2498387
[TBL] [Abstract][Full Text] [Related]
8. Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats.
Matsubara K; Abe K; Irie T; Uekama K
J Pharm Sci; 1995 Nov; 84(11):1295-300. PubMed ID: 8587046
[TBL] [Abstract][Full Text] [Related]
9. Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-beta-cyclodextrin.
Abe K; Irie T; Uekama K
Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2232-7. PubMed ID: 8582025
[TBL] [Abstract][Full Text] [Related]
10. Conscious and anaesthetised Göttingen mini-pigs as an in-vivo model for buccal absorption - pH-dependent absorption of metoprolol from bioadhesive tablets.
Meng-Lund E; Jacobsen J; Andersen MB; Jespersen ML; Karlsson JJ; Garmer M; Jørgensen EB; Holm R
Drug Dev Ind Pharm; 2014 May; 40(5):604-10. PubMed ID: 24724915
[TBL] [Abstract][Full Text] [Related]
11. Disposition of the 3H-labeled gonadotropin-releasing hormone analog buserelin in rats.
Berger H; Sandow J; Heinrich N; Albrecht E; Kertscher U; Oehlke J
Drug Metab Dispos; 1993; 21(5):818-22. PubMed ID: 7902242
[TBL] [Abstract][Full Text] [Related]
12. Preparation and properties of buserelin suspensions.
Ryszka F; Dolińska B; Szulc B; Zientarska G
Boll Chim Farm; 1994 Mar; 133(3):156-9. PubMed ID: 8011275
[TBL] [Abstract][Full Text] [Related]
13. Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa.
Jin L; Boyd BJ; Larson IC; Pennington MW; Norton RS; Nicolazzo JA
J Pharm Sci; 2016 Jul; 105(7):2173-9. PubMed ID: 27312508
[TBL] [Abstract][Full Text] [Related]
14. Peroral delivery systems based on superporous hydrogel polymers: release characteristics for the peptide drugs buserelin, octreotide and insulin.
Dorkoosh FA; Coos Verhoef J; Ambagts MH; Rafiee-Tehrani M; Borchard G; Junginger HE
Eur J Pharm Sci; 2002 Jun; 15(5):433-9. PubMed ID: 12036720
[TBL] [Abstract][Full Text] [Related]
15. In vitro, ex vivo and in vivo examination of buccal absorption of metoprolol with varying pH in TR146 cell culture, porcine buccal mucosa and Göttingen minipigs.
Holm R; Meng-Lund E; Andersen MB; Jespersen ML; Karlsson JJ; Garmer M; Jørgensen EB; Jacobsen J
Eur J Pharm Sci; 2013 May; 49(2):117-24. PubMed ID: 23500040
[TBL] [Abstract][Full Text] [Related]
16. Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases.
Jin L; Boyd BJ; White PJ; Pennington MW; Norton RS; Nicolazzo JA
J Control Release; 2015 Feb; 199():37-44. PubMed ID: 25482338
[TBL] [Abstract][Full Text] [Related]
17. Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system.
Langoth N; Kahlbacher H; Schöffmann G; Schmerold I; Schuh M; Franz S; Kurka P; Bernkop-Schnürch A
Pharm Res; 2006 Mar; 23(3):573-9. PubMed ID: 16411147
[TBL] [Abstract][Full Text] [Related]
18. Disposition of 3H-labelled buserelin continuously infused into rats.
Heinrich N; Albrecht E; Sandow J; Kertscher U; Lorenz D; Oehlke J; Berger H
Eur J Drug Metab Pharmacokinet; 1996; 21(4):345-50. PubMed ID: 9074900
[TBL] [Abstract][Full Text] [Related]
19. Oral Biodisposition Study of Ritodrine after Its Buccal Administration in Rats.
Onishi H; Yumoto K; Sakata O
Curr Drug Deliv; 2017; 14(5):634-640. PubMed ID: 28128069
[TBL] [Abstract][Full Text] [Related]
20. New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies.
Giannola LI; Paderni C; De Caro V; Florena AM; Wolff A; Campisi G
Curr Pharm Des; 2010; 16(6):653-9. PubMed ID: 20388075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
